In lung adenocarcinoma, the low YTHDF2 group was mainly enriched in immunity-related signaling pathways (inflammatory response, IL6-JAK-STAT3 signaling, allograft rejection, and IL2-STAT5 signaling). This evidence concerns the gene IL2 and lung adenocarcinoma.